Aytu Biopharma (AYTU) Non-Current Deferred Tax Liability (2015 - 2023)

Aytu Biopharma (AYTU) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $100000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $100000.0 in Q2 2023; TTM through Jun 2023 was $100000.0, a 0.0% change from a year earlier, with the FY2023 full-year figure at $100000.0, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was $100000.0 for Q2 2023 at Aytu Biopharma, roughly flat from $100000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $200000.0 in Q2 2021 and troughed at $100000.0 in Q3 2021.
• A 3-year average of $120000.0 and a median of $100000.0 in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability sank 50.0% in 2022 and changed 0.0% in 2023, its largest moves.
• Over 3 years, Non-Current Deferred Tax Liability stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $100000.0 (Q2 2023), $100000.0 (Q2 2022), and $100000.0 (Q4 2021), per Business Quant data.